In a research note titled "I'm Vexxyed By TXMD's Stock Price," Cantor Fitzgerald analyst Louise Chen reaffirms an Overweight rating on TherapeuticsMD with a $27 price target. The execution of the Imvexxy, Bijuva and Annovera launches is underappreciated, Chen tells investors. She thinks peak sales could exceed "modest expectations for the three drugs that target large unmet needs." Discussions with two experienced OB-GYNs that have already prescribed Imvexxy and are excited to prescribe Bijuva and Annovera support a positive investment thesis on the stock, adds the analyst.